Abstract 1908
Background
TITAN evaluated APA vs placebo (PBO), + ADT, in pts with mCSPC. APA improved overall survival (OS [HR, 0.67; 95% CI, 0.51-0.89; p = 0.0053]) vs PBO. We evaluated AR aberrations at baseline (BL) and end of treatment (EOT) and assessed associations of EOT AR aberrations with outcomes in TITAN.
Methods
From 265 pt samples (APA, n = 116; PBO, n = 149) available for evaluation, a subset was analyzed for circulating tumor (ct)DNA and AR aberrations (ARv7, AR amplification, AR ligand binding domain mutations) from cell-free (cf)DNA and cfRNA using next-generation sequencing and PCR, respectively. Associations with OS and duration on first subsequent therapy were assessed.
Results
BL characteristics of pts were balanced between biomarker-positive groups. Among aberrations at BL, AR amplification was associated with longer duration of prior ADT (4.2 mo vs 1.6 mo, pts with vs without AR amplification; p = 0.034). ctDNA % and frequency of AR aberrations increased from BL to EOT. At EOT, ctDNA % was similar in APA and PBO groups (60% and 66%), and AR aberrations were less frequent with APA vs PBO (Table). Regardless of treatment group, OS was significantly shorter with detection of any AR aberration at EOT (OS: 2.7 [1.1-6.6], p = 0.0278, APA; 6.1 [1.9-20.3], p = 0.0007, PBO). Detection of any AR aberration at EOT was significantly associated with duration on first subsequent therapy (2.0 [1.0-4.0], p = 0.0386).Table:
883P Frequency of AR aberrations at BL and EOT
BL | EOT | |||
---|---|---|---|---|
n, (n/N%) | APA + ADT | PBO + ADT | APA + ADT | PBO + ADT |
ARv7 | 2/15 (13) | 6/44 (14) | 9/46 (20) | 29/81 (36) |
AR mutation | 0 | 0 | 4/46 (9) | 7/81 (9) |
AR amplification | 1/15 (7) | 6/44 (14) | 19/46 (41) | 42/81 (52) |
Any AR aberrationa | 3/15 (20) | 10/44 (23) | 22/46 (48)b | 54/81 (67) |
Only pts with ARv7, AR amplification, and AR mutation measured are reported. bFrom Fisher’s exact test for comparison vs PBO, p = 0.04.
Conclusions
In TITAN, AR amplification at BL was associated with even brief ADT exposure. AR aberrations were fewer at EOT with APA vs PBO. Pts with AR aberrations at EOT had worse outcomes vs pts without. Taken together, these findings suggest that early APA + ADT provides long-term benefits vs ADT alone without increased acquisition of AR aberrations. The detailed biological mechanisms underlying these findings need to be further studied.
Clinical trial identification
NCT02489318.
Editorial acknowledgement
Larissa Belova, PhD, of Parexel.
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Disclosure
K.N. Chi: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Essa; Advisory / Consultancy, Research grant / Funding (institution): Lilly/ImClone; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Tokai Pharmaceuticals; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Essa; Advisory / Consultancy, Research grant / Funding (institution): Lilly/ImClone; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Tokai Pharmaceuticals. S. Thomas: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. N. Agarwal: Advisory / Consultancy: Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Research grant / Funding (institution): Active Biotech; Amgen; AstraZeneca; Bavarian Nordic; Bayer; BN ImmunoTherapeutics; Bristol-Myers Squibb; Calithera Biosciences; Celldex; Eisai; Exelixis; Genentech; GlaxoSmithKline; Immunomedics; Janssen; Medivation; Merck; Newlink Geneti. F. Feng: Leadership role, Shareholder / Stockholder / Stock options: PFS Genomics; Advisory / Consultancy: Dendreon; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Janssen Oncology; Advisory / Consultancy: Ferring Pharmaceuticals; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Bayer HealthCare Pharmaceuticals; Advisory / Consultancy: Blue Earth Diagnostics; Advisory / Consultancy: Celgene; Advisory / Consultancy: Medivation/Astellas Pharma; Research grant / Funding (institution): Zenith Epigenetics; Licensing / Royalties, I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer; it is in the process of being licensed to PFS Genomics, a company that I helped found: Patents, Royalties, Other Intellectual Property. G. Attard: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas Pharma; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Medivation; Advisory / Consultancy, Travel / Accommodation / Expenses: Abbott Laboratories; Advisory / Consultancy: ESSA; Advisory / Consultancy: Janssen-Cilag; Advisory / Consultancy: Millennium; Advisory / Consultancy: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ventana Medical Systems; Advisory / Consultancy: Veridex; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Takeda; Research grant / Funding (institution): Arno Therapeutics; Licensing / Royalties: The Institute of Cancer Research Rewards to Inventors list of abiraterone acetate; Non-remunerated activity/ies, Other relationship: Institute of Cancer Research. A.W. Wyatt: Advisory / Consultancy: Genzyme; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Janssen. M. Gormley: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. D.S. Ricci: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. A. Lopez-Gitlitz: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. K. Deprince: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. J. Larsen: Full / Part-time employment: Janssen; Shareholder / Stockholder / Stock options: Johnson & Johnson. W. Chen: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. B. Miladinovic: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. V. Naini: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. S. Chowdhury: Honoraria (self), Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy: Janssen-Cilag; Honoraria (self): Novartis; Research grant / Funding (institution): Sanofi/Aventis.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract